Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FCGR2B/CD32b drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCGR2B (CD32b) ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View FCGR2B Products |
| Selectivity Panel | FCGR2A (CD32a) ECD-Fc Protein For strict counter-screening against activating ortholog (96% homology). Sequence Verified. |
View FCGR2A Products |
| Gene Delivery | FCGR2B Lentivirus Premade Particles / Promise-ORF Full-length ORF for stable cell line construction. High-titer, sequence verified. |
View FCGR2B Products |
| Benchmark Ab | Anti-FCGR2B Reference Antibody (Clinical Biosimilar Sequence, e.g., BI-1206) Recombinant positive control for blocking assays. |
View FCGR2B Products |
| Validator | FCGR2B siRNA Set For knockdown verification and specificity controls. |
View FCGR2B Products |
| Related Target A | FCGR2A (CD32a) Activating FcγR, critical for selectivity screening. |
View FCGR2A Products |
| Related Target B | FCGR3A (CD16a) Low-affinity activating FcγR; essential for ADCC and off-target liability screening. |
View FCGR3A Products |
| Related Target C | FCGR1A (CD64) High-affinity FcγR; cross-reactivity assessment for broad Fc-blocking agents. |
View FCGR1A Products |
| Related Target D | CD20 Standard combination therapy target in B-cell malignancies. |
View CD20 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FCGR2A/2B Selectivity Discrimination (96% ECD homology) | Matched Human FCGR2A and FCGR2B ECD Proteins (>95% purity, theoretical MW confirmed, Mass Spec verified identity) |
| Cross-species Reactivity (Cynomolgus/Mouse, IND-enabling) | Human/Cyno/Mouse Ortholog Pair available (HEK293 expressed, preserving native glycosylation patterns essential for Fc binding) |
| Receptor Occupancy Assay Standards | High-concentration FCGR2B Protein (Low endotoxin <1EU/µg, suitable for PK/PD modeling and competition assays) |
| False Positives / Non-specific Binding | FCGR2B-specific siRNA Set for target specificity validation in cell-based assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay validation |
Live FCGR2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FCGR2B-targeted therapeutics is intensifying around the "blocking the blocker" hypothesis—preventing the inhibitory ITIM signaling that dampens humoral immunity. As first-generation antibodies (e.g., BI-1206) advance through Phase II for systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), and B-cell malignancies, the next wave of R&D focuses on bispecific constructs pairing FCGR2B blockade with PD-L1 or CD20 targeting to enhance tumoricidal activity, and Fc-engineered platforms leveraging FCGR2B cross-linking to potentiate immune agonists (e.g., CD40, DR5).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking mAb (Antagonist) | BioInvent (BI-1206), Macrogenics, Roche | SLE, ITP, NHL, CLL, Autoimmune Hemolytic Anemia | Selectivity vs FCGR2A (Need discriminating antigens with <2% cross-reactivity) |
| Bispecific (PD-L1/FCGR2B, BCR/FCGR2B) | Bristol Myers Squibb (concept), Xencor, MacroGenics | Solid Tumors, Autoimmune (SLE) | Co-engagement validation (Need stable cell lines expressing both targets) |
| Fc-Engineered Biologics (Agonism support) | Xencor, Momenta (J&J) | Refractory Autoimmunity, Solid Tumors | Affinity discrimination (SPR/BLI with FCGR2B vs FCGR2A/3A panels; need FCGR2B variants) |
Key Genetic Variants & Biomarkers
FCGR2B harbors clinically relevant polymorphisms that impact drug development:
- Ile232Thr (rs1050501): Risk factor for systemic lupus erythematosus (SLE); confers resistance to malaria; found at increased frequency in certain populations. This variant affects receptor internalization and signaling, making it a critical biomarker for patient stratification.
- Other SNPs: rs5017567 and rs1050499 are also documented in UniProt P31994 and may influence expression or function.
The two Ig-like C2-type domains (domain 1 and domain 2) constitute the extracellular ligand-binding region, essential for antibody epitope mapping and functional assays.